Bristol-Myers Squibb gets FDA breakthrough therapy status for Orencia to prevent GvHD

[cafead]

via Bristol-Myers Squibb (BMS) has secured breakthrough therapy status from the US Food and Drug Administration (FDA) for its Orencia (abatacept) to prevent moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors.

article source